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Strengths and limitations of this study
 ► It is the first overview of research guidance on ex-
ploring, confirming and interpreting subgroup ef-
fects by key organisations.
 ► All organisations included in the review were con-
tacted in an attempt to receive the most up-to-date 
guidance documents.
 ► Although organisations were included from different 
continents, the search was limited to English guide-
lines or translated documents.
 ► Due to the wide variety of organisations, a system-
atic review of all organisations and documents was 
not feasible.
AbStrACt
Objectives With the increasing interest in personalised 
medicine, the use of subgroup analyses is likely to 
increase. Subgroup analyses are challenging and 
often misused, possibly leading to false interpretations 
of the effect. It remains unclear to what extent key 
organisations warn for such pitfalls and translate current 
methodological research to detect these effects into 
research guidelines. The aim of this scoping review is 
to determine and evaluate the current guidance used by 
organisations for exploring, confirming and interpreting 
subgroup effects.
Design Scoping review.
Eligibility criteria We identified four types of key 
stakeholder organisations: industry, health technology 
assessment organisations (HTA), academic/non-profit 
research organisations and regulatory bodies. After 
literature search and expert consultation, we identified 
international and national organisations of each type. For 
each organisation that was identified, we searched for 
official research guidance documents and contacted the 
organisation for additional guidance.
results Twenty-seven (45%) of the 60 organisations that 
we included had relevant research guidance documents. 
We observed large differences between organisation types: 
18% (n=2) of the industry organisations, 64% (n=9) of 
the HTA organisations, 38% (n=8) of academic/non-profit 
research organisations and 57% (n=8) of regulatory 
bodies provided guidance documents. The majority of 
the documents (n=33, 63%) mentioned one or more 
challenges in subgroup analyses, such as false positive 
findings or ecological bias with variations across the 
organisation types. Statistical recommendations were less 
common (n=19, 37%) and often limited to a formal test of 
interaction.
Conclusions Almost half of the organisations included 
in this scoping review provided guidance on subgroup 
effect research in their guidelines. However, there were 
large differences between organisations in the amount 
and level of detail of their guidance. Effort is required to 
translate and integrate research findings on subgroup 
analysis to practical guidelines for decision making and 
to reduce the differences between organisations and 
organisation types.
IntrODuCtIOn
Individuals may respond to medical interven-
tions in different ways due to genetic, environ-
mental, demographic, disease, behavioural, 
or comorbidity variations that strengthen or 
weaken the outcome of a treatment. Patients 
with similar variations can be grouped in 
so-called subgroups of patients that respond 
better or worse to medical interventions. In 
order to tailor medical treatment to an indi-
vidual, personalised medicine aims to provide 
patients with the most relevant and optimal 
treatment, possibly resulting in better patient 
outcomes and/or lower medical costs.1 2 
Interest in subgroup effects is likely to grow 
as more information becomes available from 
biomarkers, companion diagnostics, high-res-
olution imaging, function tests, and genetic 
information. However, investigating subgroup 
effects can be complex and challenging as 
there is a natural tension between the urge to 
detect clinically relevant subgroup effects and 
avoiding incorrect claims.3 4
Given both the complexity and relevance 
of investigating subgroup effects, many 
papers have been published in the scientific 
literature on this topic, both methodological 
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and statistical, with new methods to adequately detect 
subgroups.5–7 Although reaching a consensus regarding 
the optimal method can be challenging,8 several published 
reviews tried to provide guidance by focusing either on 
the current practice of subgroup analyses, giving an over-
view of (competing) statistical approaches or providing 
direction on best practices.3 9 10 However, it remains 
unclear to what extent key organisations (stakeholders 
with respect to the issue of subgroup analyses) translate 
recommendations from methodological research into 
practical guidance. These key organisations may be inter-
ested in subgroup effects as they either have a regulatory 
function, are part of an academic organisation, produce 
medicines and/or other treatments or generate evidence 
on the (cost-)effectiveness of treatments used in decision 
making required to determine whether treatments may 
be reimbursed or introduced on the market. We assume 
that these organisations provide guidance on subgroup 
research for their members, to assist them in this kind of 
analyses or research.
To identify and evaluate the nature of the guidance on 
exploring, confirming and interpreting subgroup effects 
during these steps, we have performed a scoping review. 
A scoping review is a useful instrument that can be used 
to generate an overview on a broad topic to highlight the 
nature of what is being discussed, the overlap in informa-
tion and what is not discussed.11 The aim of this scoping 
review is to discover how key organisations use findings 
and recommendations from methodological research in 
their research guidance on exploring, confirming and 
interpreting subgroup effects. We focus specifically on 
their definition of subgroup effects, level of detail in the 
guidance, the inclusion of factors affecting the credibility 
of subgroup effects and the promoting or discouraging of 
specific statistical approaches.
MEthODS
We investigated how subgroup effect research has been 
included in research guidelines written by a wide range 
of key organisations worldwide. Since numerous organi-
sations exist worldwide, it was not feasible to analyse all of 
them. Therefore, we restricted the inclusion to the major 
types of stakeholders in this field (see criteria below) 
and adopted a scoping review design.2 11 We followed 
the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses extension for Scoping Reviews (PRIS-
MA-ScR) checklist in reporting our results.12
Organisations eligibility criteria
We identified four main types of organisations that repre-
sent major stakeholders with a clear interest in subgroup 
effects of medical treatment: (1) industry (developing the 
medical treatment), (2) health technology assessment 
(HTA) organisations (evaluating the cost-effectiveness), 
(3) academic/non-profit research organisations (eval-
uating effectiveness) and (4) regulatory bodies (health 
market authorisation and reimbursement). Our goal was 
to capture all organisations that are involved throughout 
the lifecycle of a medical treatment from concept to 
implementation.
Information sources
We selected a limited number of organisations focusing 
on the following regions: global (worldwide organisa-
tions), North America (USA and Canada), Europe (UK, 
Germany and The Netherlands) and Asia-Pacific (Japan 
and Australia). Other regions were not considered 
because of their limited number of HTA organisations/
regulatory bodies, due to language restrictions and to 
limit the scope of this review.13
Patient and public involvement
Patients and/or public were not involved.
Search strategy
Initially, we adopted a stakeholder list of Makady et 
al describing 23 key organisations.14 We then gradu-
ally expanded that list of potential organisations by 
contacting methodology experts in the field of subgroup 
analysis to identify specific organisations within these 
organisation types and completed the list by means of a 
literature search. The methodological experts were iden-
tified via the Cochrane collaboration methods groups, 
key opinion papers on this topic and HTA organisations. 
The key opinion papers are listed in online supplemen-
tary S1. Next, we searched for similar organisations across 
regions (eg, Food and Drug Administration (FDA) in 
USA vs European Medicines Agency (EMA) in Europe). 
We excluded organisations if: (1) they work in specific 
medical areas (eg, food safety, surgery, cardiology, 
oncology or infectious diseases); (2) their mission was not 
related to the purpose of this review, (3) they only collect 
guidelines from other organisations, rather than produce 
their own or (4) they only had non-English documents. 
For each organisation, we used the following strategy to 
determine whether they had official documents in which 
they provide research guidance: (1) using the search 
engine of their official website, (2) Google, (3) PubMed 
and (4) citations. Documents were considered eligible if 
they contained methodological research guidance and 
included ‘subgroup’, or terms analogous to the defini-
tion of subgroup research: investigate treatment effect 
according to baseline characteristics, covariate treat-
ment interaction, heterogeneity, effect modifying factors, 
split the population into subgroup or explicitly mention 
particular characteristics should be analysed or presented 
separately (eg, gender). The research strategy is included 
in online supplementary S2.
Additionally, all organisations were contacted by email 
or contact form, asking whether they have any research 
guidance on subgroup effects or an updated version of 
the ones we already found. If there was no response after 
one reminder email, we discontinued the search for that 
specific organisation.
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A guidance document was considered to be official 
when it clearly named the organisation, displayed the 
logo prominently or included statements about publica-
tion rights. We excluded books, talks or lectures written 
by individual author(s) even when they worked or 
conducted projects for the organisation. When an organi-
sation published multiple versions of the same document, 
we only included the most recent version.
Data extraction
Out of the included documents, we extracted data on the 
following topics: general information about the organi-
sation, purpose and context of the guidance documents, 
definitions and concepts of subgroup analysis chal-
lenges and recommendations for and against specific 
methods. Data extraction was performed in two stages: 
first, all documents were scanned to detect whether they 
mention the predefined topics. Second, we analysed the 
documents in more detail. Any information on subgroup 
research was extracted. Subsequently, the 10 credibility 
criteria described by Sun et al to investigate the credibility 
of authors’ claims of subgroup effects were used to deter-
mine if and how subgroup analysis credibility criteria were 
reported.5 These criteria were used because they were up 
to date, widely accepted, well defined, and the multiple 
criteria enabled us to compare the documents. Although 
these criteria were developed to assess the credibility of 
subgroup effects in randomised controlled trials, we used 
these to determine whether these topics were mentioned 
in any document, including documents aimed at non-ran-
domised trials or systematic reviews. The criteria were 
based on previous published subgroup credibility criteria 
that were focused on subgroup analyses in general and 
are thus also applicable to other types of data.15 16 The 
data extraction method, including the definitions of 
general and detailed information, are described in online 
supplementary S3.
Analysis
Using descriptive statistics, similarities and differences 
between the types of organisations and regions were 
analysed. The frequency of similar recommendations was 
analysed and compared. We analysed the frequency at 
which the credibility criteria for subgroup analysis were 
mentioned and calculated the average number of criteria 
mentioned in the documents for the four organisation 
types.5
rESultS
From the list of organisations of Makady et al and initially 
received suggestions, 40 organisations were included. 
Thirty-four organisations were added after expert consul-
tation and inclusion of counterpart organisations. In 
total, after removing organisations outside the scope of 
our search strategy, we found 60 organisations operating 
globally or in one of the prespecified regions or countries 
that matched our inclusion criteria (figures 1 and 2).
In the end, we included 11 industry organisations, 14 
HTA organisations, 21 academic/non-profit research 
organisations and 14 regulatory bodies divided over 
global organisations (23%), Europe (32%), North 
America (27%) and Asia-Pacific (18%). Out of the 60 
organisations, 27 (45%) had relevant research guidance 
documents and 26 (43%) responded to our inquiry. Five 
organisations responded but stated that they had no 
documents and six organisations of whom we received no 
response had documents online available. The availability 
of documents differed among organisation types, with 
18%, 64%, 38% and 57% for industry, HTA, academic/
non-profit and regulatory organisations, respectively.
Looking at regional differences, Europe and North 
America had relevant research guidance documents 
in half of the organisations we included, with 53% and 
50% of the organisations, respectively, while Asia-Pacific 
had research guidance in 27% of the organisations. In 
total, we retrieved two documents from industry organ-
isations,17 18 19 documents from HTA organisations,19–37 
12 documents from academic organisations38–49 and 19 
documents from regulatory organisations.50–68 Eleven 
documents were excluded because they were not in line 
with our research objective, including presentations, 
advertisement guidelines or political documents. The 
list of the included organisations and documents can be 
found in online supplementary S4.
Document details
The general characteristics of the included documents 
are described in table 1. The mean and median year of 
publication of the documents were 2011 and 2014 (range: 
1988–2018), respectively. HTA and regulatory organisa-
tions had the most documents (n=19) and industry organ-
isations the least (n=2). A separate section on subgroup 
research was present in 0%, 42%, 17% and 42% of the 
industry, HTA, academic and regulatory documents, 
respectively. Both, a definition of subgroups and hetero-
geneity, appeared more often when a separate subgroup 
section was available. Regulatory bodies included the 
most clinical trial guidance of the organisation types 
(n=19, 37%) but had no guidance on non-randomised 
studies. In total, out of the 52 documents, five were aimed 
at non-randomised studies (10%), three by HTA and 2 by 
academic organisations. HTA organisations were the only 
type of organisation that had documents for cost-effec-
tiveness studies (n=10, 19%). Both included documents 
from industry organisations were aimed at clinical trials.
types of subgroup effects
The term subgroup effects can be related to a range of 
different concepts. Therefore, organisations typically 
distinguish between different types of subgroup effects, 
such as subgroup effects from exploratory analysis, 
subgroup effects from confirmatory analysis, qualitative 
effects and quantitative effects.10 69 These concepts are 
elucidated in box 1.
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Figure 1 PRISMA flow chart of organisation and document inclusion and analysis. PRISMA, Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses.
Subgroup effects from exploratory analyses were 
mentioned most often by the organisations, in 23 (44%) 
of all documents, divided in 0%, 58%, 25% and 47% for 
industry, HTA, academic and regulatory organisations, 
respectively. Guidance for exploratory subgroup analysis 
mostly advised to compare different treatment effects in 
gender or age.
Subgroup effects from confirmatory subgroup anal-
yses were described in 13 documents (25%), divided in 
0%, 42%, 17% and 16% for industry, HTA, academic 
and regulatory organisations. One document suggested 
to report the 95% prediction interval in confirmatory 
subgroup analysis next to the regular 95% CI in order to 
reflect the variation of the treatment/subgroup effect in 
a different setting.
Qualitative subgroup effects and quantitative subgroup 
effects were rarely mentioned. Only HTA organisations 
mentioned both concepts in three different documents 
(14% of all HTA guidelines, 6% of all documents).
Regarding the actual clinical relevance of the subgroup 
effect, no document in our review highlighted the 
importance of reporting absolute differences between 
subgroups. That is, a significant test result (to detect a 
subgroup) may not lead to a change in treatment deci-
sions, whereas in the absence of a significant result a clin-
ically relevant subgroup may still exist.
Challenges in subgroup analysis
Performing adequate subgroup analysis can be difficult 
due to several statistical and methodological challenges. 
Informing researchers and other stakeholders about the 
challenges in subgroup analysis can be a way to improve 
the outcome of the analyses. The most common chal-
lenges are: type I errors, multiplicity problems, lack of 
power and ecological bias (explained in box 1).
Typically, these challenges were not regularly mentioned 
or discussed. Overall, the risk of a false positive (type I 
error) and multiple testing problem (multiplicity) were 
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Figure 2 Overview of organisations and their corresponding type and geographic.
most frequently mentioned, by 12 (23%) and 13 (25%) 
documents, respectively. Some documents suggest that 
limited testing or multiplicity adjustment is required. 
Next to the multiplicity and false positive issue, five docu-
ments (10%) mentioned the lack of power to detect real 
subgroup effects due to small sample sizes, increasing the 
risk of false negatives. Ecological bias was mentioned in 
three documents (6%). Lack of power and ecological bias 
was only mentioned by HTA and academic organisations.
Credibility criteria
In 1992, years before the publication of most documents 
included in our review, Oxman and Guyatt suggested 
seven criteria to assess subgroup effects.16 Sun et al 
updated the list resulting in 10 criteria for randomised 
trials to evaluate the credibility of subgroup analyses.5 
These include: (1) hypothesis specified a priori, (2) 
subgroup variable a baseline characteristic, (3) subgroup 
stratification factor at randomisation, (4) independent 
interactions, (5) consistent with previous studies, (6) 
consistent across outcomes, (7) small number of tests, 
(8) significant p value of interaction test, (9) indirect 
evidence to support apparent effect and (10) direction of 
subgroup effect prespecified. We assessed how the docu-
ments reflect the credibility criteria. In total, 34 docu-
ments (62%) mentioned one or more credibility criteria. 
On average, HTA documents included 4.1 criteria, while 
the averages for industry, academic and regulatory organi-
sation documents were lower with 1.5, 2.3 and 1.8 criteria, 
respectively (as shown in figure 3).
Of the 10 criteria, ‘Hypothesis specified a priori’ 
and ‘Subgroup variable a baseline characteristic’ were 
addressed most frequently, in 33 (63%) and 29 (56%) of 
the documents, respectively. ‘Direction of subgroup effect 
prespecified’ was mentioned the least (six times, 12%).
Statistical recommendations
Statistical recommendations were often lacking, and 
when present, not up-to-date with current standards. The 
recommendations were limited to a formal test of interac-
tion using a threshold of p < 0.05 (16 documents (31%)) 
and/or stratified analyses (nine documents (17%)). One 
document described the option to use Bayesian models 
in a subgroup analysis.30 In total, 37% of the documents 
provided statistical recommendations. There were no 
recommendations against certain statistical tests or 
methods.
Publication checklists
There are several checklists/guidelines for reporting 
trials or reviews created to strengthen the reporting of 
medical studies. These checklists are often combined 
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Table 1 General characteristics of the included documents
Type
Industry
(N=11)
HTA
(N=14)
Academic
(N=20)
Regulatory
(N=15)
Total
(N=60)
Total documents (n) 2 19 12 19 52
Documents per organisation ratio 0.18 1.36 0.60 1.27 0.87
Number of pages (median, first/third 
quartile)
9 (9/9) 113 (75/219) 71 (39/162) 39 (20/81) 74 (36/162)
‘Subgroup’ mentioned (median, first/third 
quartile)
1 (1/1) 24 (11/41) 5 (2/17) 12 (8/21) 13 (5/27)
‘Effect modification’ mentioned at least 
once (n, %)
0 (0) 8 (42) 2 (17) 3 (16) 13 (25)
‘Treatment covariate interaction’ mentioned 
at least once (n, %)
0 (0) 2 (11) 0 (0) 2 (11) 4 (8)
Specific subgroup paragraph (n, %) 0 (0) 8 (42) 2 (17) 8 (42) 18 (35)
Mention heterogeneity (n, %) 0 (0) 11 (58) 5 (42) 8 (42) 24 (46)
Include a subgroup definition (n, %) 0 (0) 9 (47) 3 (25) 8 (42) 20 (38)
Research purpose:* (n, %)
  Cost-effectiveness study (n, %) 0 (0) 10 (53) 0 (0) 0 (0) 10 (19)
  Clinical trial (n, %) 2 (100) 9 (47) 7 (58) 19 (100) 37 (71)
  Non-randomised study (n, %) 0 (0) 3 (16) 2 (17) 0 (0) 5 (10)
  Systematic review (n, %) 0 (0) 9 (47) 5 (42) 7 (37) 21 (40)
Note: Presented as frequency.
*Some documents had multiple research purposes.
HTA, health technology assessment; N, number of organisations; n, number of documents.
with a statement that includes best practices for research 
publication, including optimal methods for subgroup 
analysis reporting.
In our search, we found that 13 documents (25%) 
recommended the Preferred Reporting Items for 
Systematic Reviews and Meta-analyses (PRISMA) check-
list for systematic reviews, 12 documents (23%) recom-
mended the Consolidated Standards of Reporting Trials 
(CONSORT) checklist for randomised trials, 10 docu-
ments (19%) recommended the Strengthening the 
Reporting of Observational Studies in Epidemiology 
(STROBE) checklist for observational studies and the 
Consolidated Health Economic Evaluation Reporting 
Standards (CHEERS) statement for economic evalua-
tions was mentioned in two documents (4%). Documents 
that described a checklist often described more than one; 
29 documents (56%) did not recommend any checklist 
or guidance for publication.
Individual patient data
Like we mentioned before, detecting patient subgroups 
can be difficult due to the limited number of patients 
that have been included in studies. To overcome this 
problem, researchers may perform a review to identify 
and analyse the individual patient data from multiple 
trials. This approach is also known an individual patient 
data meta-analysis (IPDMA).70 Of the 52 documents, 
five (9.6%) describe the IPDMA as a method to detect 
subgroups, and only one document provided method-
ological guidance on IPDMA.
DISCuSSIOn
This scoping review provides insight into the adoption of 
methodological subgroup effects research in guidelines, 
both by international and national key organisations. 
Investigating subgroup effects can be challenging and 
resulted in the publication of several non-reproducible 
subgroup effects.71–73 With the growing discussion on 
adequate subgroup analysis,4 10 proper guidance could 
reduce the number of non-reproducible findings and 
improve individual patient care. However, only 45% of 
the 60 organisations included in our review had some 
guidance documents on subgroup analysis research, with 
large differences between organisation types. Overall, 
HTA organisations provided most documents with 
detailed and up-to-date methodological information, 
while industry organisations provided hardly any guid-
ance documents, possibly because these organisations 
use research guidance from other organisations (eg, 
regulatory organisations). Organisations that included 
subgroup analysis in their guidelines often only mention 
subgroup research as a tool to evaluate heterogeneity 
between (sub)groups.
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box 1. Summary of types of subgroup effects and 
challenges in subgroup analyses
types of subgroup effects:
 ► Confirmatory: subgroup effects from confirmatory analyses are sub-
group effects that have been detected in previous trials and require 
confirmation of the effect in another population that is sufficiently 
powered to detect the subgroup, increasing credibility of the sub-
group effect.
 ► Exploratory: subgroup effects from exploratory analyses are sub-
group effects that are detected during post hoc analysis in a trial 
or review, without prior knowledge of the effect or predefining the 
direction of the subgroup effect.
 ► Qualitative subgroup effects: treatment effects that are beneficial to 
one subgroup but harmful in another.
 ► Quantitative subgroup effects: difference in size of treatment effect 
between subgroups but not the direction. For example, a treatment 
can be beneficial across different age ranges but to a larger extent 
for the elderly (as compared to adolescents).
Challenges in subgroup analyses:
 ► Type I error (false positive): statistical tests for detecting subgroup 
effects typically involve a null hypothesis that assumes absence of 
treatment–covariate interaction. The significance level is the prob-
ability of rejecting the null hypothesis when it is true. For instance, 
when the significance level is set to 0.05 (5%), then, if there is in-
deed no treatment-covariate interaction, there is a 5% chance of 
incorrectly rejecting the null hypothesis. This probability to make 
a type I error can be decreased by lowering the significance level, 
which also decreases the power to detect a genuine treatment-co-
variate interaction.
 ► Type II error (false negative): a type II error occurs when the null 
hypothesis is false (ie, treatment–covariate interaction is present) 
but is not rejected. The probability to make a type II error is related 
to the power and can be reduced by increasing the significance level 
or the sample size.
 ► Multiplicity: when multiple (related) hypothesis tests are performed 
in a single dataset, the probability of at least one type I error increas-
es. This is a common problem when assessing effect modification 
by more than 1 covariate. If the study is not properly powered to de-
tect treatment–covariate interaction, it can also increase the proba-
bility of making at least one type II error (failure to reject a false null 
hypothesis: a false negative). Multiplicity problems can be resolved 
by statistical multiplicity correction (eg, based on family-wise error 
rates) or reducing the number of (exploratory) subgroup analyses 
(which need to be prespecified).
 ► Power: the power is the probability that an effect is found assuming 
there is an effect. When a study is not powered for subgroup anal-
yses, splitting the study population into different subgroups could 
result in a lack of power. This means that the risk of a type II error 
increases (false negative finding).
 ► Ecological bias: ecological bias may occur in systematic reviews 
when the presence of treatment–covariate interaction is assessed 
across studies (rather than within studies). For instance, meta-re-
gression can be used to assess whether published treatment effect 
estimates are associated with a particular population characteristic 
(eg, the proportion of males in each trial). Although the presence 
of such trial-level association is commonly treated as evidence of 
treatment–covariate interaction, this is often misleading. For in-
stance, even if gender does not have any effect on treatment effi-
cacy, a trial-level association between treatment effect and gender 
Continued
box 1 Continued
may still appear when trials that included relatively more males ad-
opted a higher treatment dosage for the active comparator.
Figure 3 Total number of credibility criteria per organisation 
type. Hypothesis specified a priori was mentioned most 
often. HTA organisations included the most credibility criteria, 
while industry organisations rarely included these criteria. 
HTA, health technology assessment.
Our assumption was that most organisations would 
include some guidance on how to perform credible 
subgroup analysis, both for exploratory and confirmatory 
reasons. However, most documents lacked detail, espe-
cially regarding statistical and methodological recommen-
dations. Given that research in personalised medicine is 
growing, we hope that key organisations will update and 
refine their guidance and at least include the credibility 
criteria of Sun et al.5
Multiple sources for research guidance can be useful, 
however, it can also increase confusion if the suggestions 
for subgroup research differ between documents and/or 
key organisations and do not include the latest recommen-
dations. More consistency in recommendations would 
help to reduce reproducibility issues and likely improve 
reporting standards. Perhaps we should strive to a more 
coherent set of guidance distinguishing between different 
main purposes for performing subgroup analyses.
In our search for official guidance documents, some 
organisations had papers that stated that the findings 
and conclusions in these documents were those of the 
authors and that the findings and conclusions did not 
necessarily represent the views of the key organisation. 
Still, we included those documents in our review because 
they were located on the official website and often were 
presented with an official logo of the organisation/
company.
Although most documents were written in the last 10 
years, a delay can exist between methodological publica-
tions and the implementation of this research into guide-
lines. However, methodological and statistical difficulties 
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in subgroup analyses have been reported over the last 
three decades.16 73 74
Strengths and limitations
This is the first scoping review targeted at guidance on 
exploring, confirming and interpreting subgroup effects 
by key organisations. The scoping review is a useful instru-
ment that can be used to generate an overview of avail-
able guidance documents by different organisations in 
different regions of the world. As recommended by Levac 
et al, we kept the research question broad and simultane-
ously considered the different concepts of interest.75 To 
balance between feasibility and comprehensiveness, we 
arranged regular meetings with methodological experts 
to discuss and justify decisions and, if needed, adapt the 
search strategy.
Some potential limitations should also be discussed. 
First, our review was targeted at research guidance docu-
ments. To search for these documents, we primarily used 
the official website of the concerning organisations. 
This might have limited the number of documents in 
our review to documents that were publicly available on 
their website. To overcome this, we tried to contact all 
organisations in an attempt to receive the most up-to-date 
documents. We limited the number of reminder emails 
to two to ensure the practicality of the scoping review. 
Second, out of the 26 organisations that responded to our 
inquiry, 21 (81%) had documents. This might indicate 
that organisations without documents might be less likely 
to respond to our email or that they had documents but 
not openly available and were not willing to respond. This 
could lead to bias as we marked these latter organisations 
as ‘no documents’, which would be an underestimation 
of the results.
Third, although we included organisations from 
different continents, we limited our search to English 
guidelines or translated documents. This might have had 
a negative impact on articles from Asia-Pacific, possibly 
explaining why we found fewer organisations and guide-
lines from Asia-Pacific, compared with North America 
and Europe. Fourth, data extraction and primary analysis 
were performed by one reviewer of our research team. 
It might have improved the accuracy of the results if it 
was done by multiple researchers. However, this was not 
feasible for our review. To ensure the quality of the review, 
we discussed all discrepancies and difficulties with the 
research team during all steps of the reviewing process.
In conclusion, less than half of the organisations 
included in our scoping review did provide some kind 
of guidance on exploring, confirming and interpreting 
subgroup effects in their guidelines. Furthermore, infor-
mation was often minimal, and methodological and statis-
tical guidance of best current practices was missing. To 
further improve and speed-up personalised medicine, 
more effort is required to uniformly disseminate and inte-
grate research findings on subgroup analysis into prac-
tical guidelines for decision making.
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